Citations 2
Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma
Castellino, Sharon M. , Pei, Qinglin , Parsons, Susan K. , McCarten, Kathleen M. , Cho, Steve , Wu, Yue , Punnett, Angela , Henderson, Tara O. , Charpentier, Anne-Marie , Keller, Frank G. , Kelly, Kara M. , McCarten, Kathleen, Horton, Terzah, Dave, Hema, K Parsons, Susan , Castellino, Sharon , Hodgson, David , Horton, Terzah M. , Dave, Hema , Hoppe, Bradford S.
New England Journal of Medicine | November 2, 2022 | Volume: 387 | Issue: 18 | Pages: 1649-1660
T087: Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma
Pei, Qinglin , McCarten, Kathleen M. , Cho, Steve , Wu, Yue , Punnett, Angela , Henderson, Tara O. , Charpentier, Ann-Marie, Keller, Frank G. , Kelly, Kara M. , Castellino, Sharon M. , Parsons, Susan K. , Hodgson, David , Horton, Terzah M. , Dave, Hema , Hoppe, Bradford S.
HemaSphere | October 10, 2022 | Volume: 6 | Issue: No issue available | Pages: 40-40